BidaskClub cut shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) from a strong-buy rating to a buy rating in a report published on Wednesday morning.

A number of other equities analysts have also recently weighed in on the stock. B. Riley lifted their price target on shares of Arrowhead Pharmaceuticals from $3.00 to $4.00 and gave the stock a neutral rating in a research report on Monday. Cantor Fitzgerald set a $5.00 price objective on shares of Arrowhead Pharmaceuticals and gave the company a neutral rating in a research report on Monday. ValuEngine raised shares of Arrowhead Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, February 2nd. Chardan Capital reaffirmed a neutral rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 16th. Finally, Piper Jaffray Companies raised shares of Arrowhead Pharmaceuticals from a neutral rating to an overweight rating and set a $5.50 price objective on the stock in a research report on Monday, November 27th. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $4.13.

Shares of Arrowhead Pharmaceuticals (ARWR) traded up $0.07 during midday trading on Wednesday, hitting $5.54. 213,954 shares of the stock were exchanged, compared to its average volume of 2,310,000. The company has a market capitalization of $414.55, a PE ratio of -11.79 and a beta of 2.52. Arrowhead Pharmaceuticals has a 52 week low of $1.42 and a 52 week high of $6.75. The company has a current ratio of 3.87, a quick ratio of 3.63 and a debt-to-equity ratio of 0.03.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Tuesday, December 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The firm had revenue of $8.71 million for the quarter, compared to the consensus estimate of $7.32 million. Arrowhead Pharmaceuticals had a negative return on equity of 42.52% and a negative net margin of 116.17%. analysts forecast that Arrowhead Pharmaceuticals will post -0.67 EPS for the current fiscal year.

In related news, COO Bruce D. Given sold 20,000 shares of the business’s stock in a transaction on Monday, January 1st. The shares were sold at an average price of $3.69, for a total value of $73,800.00. Following the sale, the chief operating officer now directly owns 948,356 shares of the company’s stock, valued at approximately $3,499,433.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.60% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Allianz Asset Management GmbH lifted its position in Arrowhead Pharmaceuticals by 2.2% in the 4th quarter. Allianz Asset Management GmbH now owns 462,105 shares of the biotechnology company’s stock valued at $1,701,000 after acquiring an additional 9,985 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in Arrowhead Pharmaceuticals by 8.8% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 186,381 shares of the biotechnology company’s stock valued at $686,000 after acquiring an additional 15,132 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Arrowhead Pharmaceuticals by 252.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock valued at $192,000 after acquiring an additional 31,765 shares in the last quarter. Macquarie Group Ltd. bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at $123,000. Finally, Jane Street Group LLC bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at $130,000. 20.48% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Arrowhead Pharmaceuticals (ARWR) Lowered to “Buy” at BidaskClub” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2018/02/15/arrowhead-pharmaceuticals-arwr-lowered-to-buy-at-bidaskclub.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.